The objective is to compare the time to fulfillment of 1987 and 2010 ACR/EULAR classification criteria between female and male patients with rheumatoid arthritis (RA) and to assess the potential impact of gender on the time to DMARD therapy. Time from first provider-documented joint swelling to fulfillment of 1987 and 2010 ACR/EULAR criteria was measured in a population-based cohort of adults with incident RA, who were stratified by male or female gender. Disease characteristics, time to start of DMARD therapy, and choice of initial DMARD were compared between groups. The study included 214 patients with RA (148 females and 66 males). Median times from first joint swelling to fulfillment of 1987 (6.5 vs 2.5 days, p = 0.48) and 2010 (1 vs 0 days, p = 0.34) classification criteria were not different between female and male patients overall. There was no difference in time to first DMARD therapy in female vs male patients (15.5 vs 16 days, p = 0.90), and methotrexate was used most frequently as first DMARD in both genders (61% female vs 64% male, p = 0.76). Among the 49 female and 20 male RF/ACPA-negative patients, females experienced a higher median time from first joint swelling to fulfillment of the 1987 (65 vs 11 days, p = 0.063) and 2010 (65 vs 0 days, p = 0.035) classification criteria. Overall, there was no significant delay in meeting 1987 and 2010 ACR/EULAR classification criteria between female and male RA patients, though time to meeting both 1987 and 2010 criteria was slightly longer in males compared with females. Among seronegative patients, females experienced a significant delay to meeting 2010 criteria from first clinically detected synovitis.

中文翻译：

---

性别对类风湿关节炎分类时间的影响：基于人群的队列的回顾性分析。


目的是比较女性和男性类风湿性关节炎 (RA) 患者达到 1987 年和 2010 年 ACR/EULAR 分类标准的时间，并评估性别对 DMARD 治疗时间的潜在影响。在一组患有 RA 的成人人群中，测量了从首次出现提供者记录的关节肿胀到满足 1987 年和 2010 年 ACR/EULAR 标准的时间，这些患者按男性或女性性别进行分层。比较各组之间的疾病特征、DMARD 治疗开始时间以及初始 DMARD 的选择。该研究包括 214 名 RA 患者（148 名女性和 66 名男性）。从首次关节肿胀到满足 1987 年（6.5 天 vs 2.5 天，p = 0.48）和 2010 年（1 vs 0 天，p = 0.34）分类标准的中位时间在女性和男性患者之间总体上没有差异。女性与男性患者首次接受 DMARD 治疗的时间没有差异（15.5 天 vs 16 天，p = 0.90），并且甲氨蝶呤在两性中最常用作首次 DMARD（61% 女性 vs 64% 男性，p = 0.76） ）。在 49 名女性和 20 名男性 RF/ACPA 阴性患者中，女性从首次关节肿胀到完成 1987 年（65 天 vs 11 天，p = 0.063）和 2010 年（65 天 vs 0 天，p = 0.035）的中位时间较长) 分类标准。总体而言，女性和男性 RA 患者在满足 1987 年和 2010 年 ACR/EULAR 分类标准方面没有显着延迟，尽管与女性相比，男性达到 1987 年和 2010 年标准的时间稍长。在血清阴性患者中，从首次临床检测到滑膜炎开始，女性患者达到 2010 年标准的时间显着延迟。